Natco Pharma’s marketing partner Mylan N.V. has launched in the US the generic version of Teva’s Copaxone injection that is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS).
Mylan has launched in the US the first Glatiramer Acetate injection 40 mg/ml (three times a week injection) as well as Glatiramer Acetate injection 20 mg/ml (once daily injection), both AP-rated, substitutable generic version of Teva’s Copaxone, Natco Pharma said on Thursday.
The branded medicine is one of the most prescribed medicines for the treatment of MS, which is a chronic inflammatory disease of the central nervous system.
Shipments to customer [in the US] have commenced, said the Hyderabad-based firm that had on Wednesday announced that Mylan ANDAs for the products had been approved by US Food and Drug Administration (USFDA). Natco’ shares that on Wednesday had surged 20% on Thursday gained 2.96% to close at ₹982.60 each.
